Adicet Bio
web2Adicet Bio is a clinical-stage biotechnology company developing engineered immune-cell therapie...
About
Adicet Bio is a clinical-stage biotechnology company developing engineered immune-cell therapies for autoimmune diseases and cancers, including treatments made from donor-derived gamma delta T cells. Its lead investigational therapy, prulacabtagene leucel or prula-cel, is a chimeric antigen receptor T-cell candidate being studied in lupus and other autoimmune conditions. Unlike treatments individually manufactured from each patient's cells, its allogeneic approach is intended to support an off-the-shelf supply. The company also researches cell therapies aimed at solid tumors and is developing an in vivo CAR T platform for additional indications. Its products remain in clinical or earlier development, rather than being approved medicines sold commercially.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Adicet Bio profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy